TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Onconetix ( (ONCO) ) has issued an announcement.
On July 16, 2025, Onconetix announced a definitive merger agreement with Ocuvex Therapeutics, a biopharmaceutical company specializing in ophthalmic therapeutic candidates. The merger will result in Ocuvex shareholders receiving 90% of the equity in the combined company, with Onconetix shareholders retaining 10%. The merger is expected to enhance Onconetix’s market position by adding Ocuvex’s ophthalmic assets, including the FDA-approved Omlonti® for ocular hypertension and glaucoma, to its portfolio. The transaction is anticipated to close in the fourth quarter of 2025, pending customary approvals.
Spark’s Take on ONCO Stock
According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.
Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.
To see Spark’s full report on ONCO stock, click here.
More about Onconetix
Onconetix is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. They own Proclarix®, an in vitro diagnostic test for prostate cancer, which is approved for sale in the EU and anticipated to be marketed in the U.S. as a lab developed test through a license agreement with Labcorp.
Average Trading Volume: 299,343
Technical Sentiment Signal: Sell
Current Market Cap: $2.52M
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.